|
|
|
Insider
Information: |
Cohen Fred E |
Relationship: |
|
City: |
San Francisco |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
9 |
|
Direct
Shares |
366,218 |
|
Indirect Shares
|
4,593,263 |
|
|
Direct
Value |
$4,854,907 |
|
|
Indirect Value
|
$56,674,287 |
|
|
Total
Shares |
4,959,481 |
|
|
Total
Value |
$61,529,194 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
1
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
1.0
|
Percentage
Gain/Loss : |
0.0%
|
216.8%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Genomic Health Inc |
GHDX |
Director |
2019-11-08 |
0 |
2019-11-08 |
0 |
Premium* |
|
Five Prime Therapeutics Inc |
FPRX |
Director |
2016-01-11 |
24,807 |
2014-07-01 |
0 |
Premium* |
|
Biocryst Pharmaceuticals Inc |
BCRX |
Director |
2017-09-18 |
119,410 |
2014-08-29 |
0 |
Premium* |
|
Caredx, Inc. |
CDNA |
Director |
2023-06-16 |
132,592 |
2014-10-01 |
0 |
Premium* |
|
Intellia Therapeutics, Inc. |
NTLA |
Director |
2023-06-14 |
41,716 |
2019-03-01 |
0 |
Premium* |
|
Urogen Pharma Ltd. |
URGN |
Director |
2019-02-06 |
15,000 |
2023-07-26 |
69,339 |
Premium* |
|
Veracyte, Inc. |
VCYT |
Director |
2020-10-19 |
10,000 |
2019-08-02 |
0 |
Premium* |
|
Progyny, Inc. |
PGNY |
Director |
2024-05-23 |
22,693 |
2020-10-24 |
0 |
Premium* |
|
Kyverna Therapeutics |
KYTX |
|
2024-02-12 |
0 |
2024-02-12 |
4,523,924 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
117 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 5 of 5
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
CDNA |
Caredx, Inc. |
Director |
|
2021-01-06 |
4 |
OE |
$14.74 |
$221,100 |
D/D |
15,000 |
105,893 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
Director |
|
2021-01-20 |
4 |
OE |
$13.78 |
$275,600 |
D/D |
20,000 |
30,000 |
0 |
- |
|
CDNA |
Caredx, Inc. |
Director |
|
2021-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
1,127 |
107,020 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
Director |
|
2021-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
2,094 |
2,094 |
0 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2021-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,652 |
8,652 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
Director |
|
2022-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
5,197 |
37,291 |
0 |
- |
|
CDNA |
Caredx, Inc. |
Director |
|
2022-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
4,863 |
111,883 |
0 |
- |
|
CDNA |
Caredx, Inc. |
Director |
|
2022-10-04 |
4 |
A |
$0.00 |
$0 |
D/D |
803 |
112,686 |
0 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2022-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
3,480 |
12,132 |
0 |
- |
|
CDNA |
Caredx, Inc. |
Director |
|
2023-01-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,062 |
113,748 |
0 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2023-05-24 |
4 |
A |
$0.00 |
$0 |
D/D |
4,385 |
16,517 |
0 |
- |
|
NTLA |
Intellia Therapeutics, In... |
Director |
|
2023-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
4,425 |
41,716 |
0 |
- |
|
CDNA |
Caredx, Inc. |
Director |
|
2023-06-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,844 |
132,592 |
0 |
- |
|
URGN |
Urogen Pharma Ltd. |
Director |
|
2023-07-26 |
4 |
A |
$9.54 |
$661,494 |
I/I |
69,339 |
69,339 |
0 |
- |
|
KYTX |
Kyverna Therapeutics |
|
|
2024-02-12 |
4 |
A |
$0.00 |
$0 |
I/I |
4,523,924 |
4,523,924 |
0 |
- |
|
PGNY |
Progyny, Inc. |
Director |
|
2024-05-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,176 |
22,693 |
0 |
- |
|
GHDX |
Genomic Health Inc |
Director |
|
2010-12-09 |
5 |
A |
$0.00 |
$0 |
D/D |
133 |
48,685 |
0 |
- |
|
117 Records found
|
|
Page 5 of 5 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|